T lymphoblastic lymphoma (T-LBL) represents around 25% of all Non-Hodgkin Lymphoma (NHL) in children and is considered as a rare disease. Most patients with T-LBL typically present with mediastinal tumor. T-LBL starts in the thymus and causes an increase in its volume. The thymus is an important organ in the development of the immune system in very young children. Its action becomes negligible in adults. The cells causing tumors possess genetic lesion that promotes their proliferation and blocks their differentiation. This work focuses on the development and the treatment of a T-LBL over a period of two years. This is the interval required to study the onset of the disease, the treatment of the acute phase and the maintenance treatment. Indeed, the therapy of T-LBL is rather long with its total duration of 24 months in most protocols including induction, consolidation and maintenance therapy. After or during the treatment, patient can be cured or relapsed. Median time of relapse is one year after complete remission (range 0.2-5.9 years).
